Title: Sultopride
CAS Registry Number: 53583-79-2
CAS Name: N-[(1-Ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide
Additional Names: N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-o-anisamide
Molecular Formula: C17H26N2O4S
Molecular Weight: 354.46
Percent Composition: C 57.60%, H 7.39%, N 7.90%, O 18.05%, S 9.05%
Literature References: Dopamine D2-receptor antagonist. Prepn: C. S. Miller et al., FR M 5916; see also: G. Bulteau et al., US 3975434 (1966, 1976 both to Soc. Etudes Sci. Ind. l'Ile-de-France). Pharmacology: C. Lavelle, J. Margarit, J. Pharmacol. 5, Suppl. 2, 58 (1974); B. Bruguerolle et al., ibid. 12, 27 (1981). Clinical trial in psychosis: D. Morel, Sem. Hop. 59, 2337 (1983). GC determn in serum: A. Kamizono et al., J. Chromatogr. 567, 113 (1991). Pharmacokinetics of enantiomers: idem et al., Biol. Pharm. Bull. 16, 1121 (1993).
Derivative Type: Hydrochloride
CAS Registry Number: 23694-17-9
Manufacturers' Codes: LIN-1418
Trademarks: Barnetil (Delagrange); Barnotil (Vita)
Molecular Formula: C17H26N2O4S.HCl
Molecular Weight: 390.93
Percent Composition: C 52.23%, H 6.96%, N 7.17%, O 16.37%, S 8.20%, Cl 9.07%
Properties: Crystals from methyl ethyl ketone, mp 181-182° (Miller); also reported as crystals from ethanol, mp 190° (Bulteau).
Melting point: mp 181-182° (Miller); mp 190° (Bulteau)
Therap-Cat: Antipsychotic.
Keywords: Antipsychotic; Benzamides; Dopamine Receptor Antagonist.
Sultosilic Acid Sultroponium Sumatrol Sumbul Sunflower Seed Oil

Sultopride structure.svg
Systematic (IUPAC) name
Clinical data
AHFS/ International Drug Names
Legal status Prescription only
Routes Oral, IM
Pharmacokinetic data
Half-life 3–5 hours
CAS number 53583-79-2 N
ATC code N05AL02
PubChem CID 5357
ChemSpider 5164 YesY
KEGG D08549 YesY
Chemical data
Formula C17H26N2O4S 
Mol. mass 354.46 g/mol
 N (what is this?)  (verify)

Sultopride (Barnetil, Barnotil, Topral) is an atypical antipsychotic of the benzamide chemical class used in Europe, Japan, and Hong Kong for the treatment of schizophrenia.[1][2][3] It was launched by Sanofi-Aventis in 1976.[1] Sultopride acts as a selective D2 and D3 receptor antagonist.[4] It has also been shown to have clinically relevant affinity for the GHB receptor as well, a property it shares in common with amisulpride and sulpiride.[5]